Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$2.85
+2.2%
$2.78
$2.20
$5.80
$277.11M2.021.45 million shs1.32 million shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$11.86
-3.3%
$14.15
$5.22
$27.38
$149.29M0.41138,937 shs229,868 shs
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
$0.36
+0.8%
$0.40
$0.25
$1.78
$9.15M0.19903,911 shs243,480 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.13
+0.9%
$1.17
$0.90
$1.88
$13.10M0.5619,499 shs44,479 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+2.15%+0.71%+15.38%-4.04%-7.77%
LifeVantage Co. stock logo
LFVN
LifeVantage
-3.34%+0.68%-16.12%-39.74%+77.01%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
+0.78%-13.54%-1.87%-24.10%-75.97%
Synlogic, Inc. stock logo
SYBX
Synlogic
+0.89%-3.42%+11.33%-15.67%-36.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
1.5569 of 5 stars
3.52.00.00.02.90.00.0
LifeVantage Co. stock logo
LFVN
LifeVantage
3.9837 of 5 stars
3.51.01.72.72.11.71.3
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
4.5148 of 5 stars
3.65.00.04.80.91.71.3
Synlogic, Inc. stock logo
SYBX
Synlogic
1.7809 of 5 stars
0.05.00.00.02.21.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$10.67274.27% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50157.17% Upside
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
3.25
Buy$4.251,071.44% Upside
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AQST, SYBX, LFVN, and SNSE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/2/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/28/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$3.50 ➝ $4.00
3/28/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
3/10/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/7/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$7.00
3/7/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/7/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$57.56M4.92N/AN/A($1.59) per share-1.79
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.67$0.62 per share19.03$2.38 per share4.98
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/AN/AN/AN/A$2.60 per shareN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
$8K1,652.06N/AN/A$4.64 per share0.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$7.87M-$0.52N/AN/AN/A-59.75%N/A-33.96%N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6921.18N/A3.46%34.29%15.04%N/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$34.10M-$1.15N/AN/AN/AN/A-53.86%-46.91%N/A
Synlogic, Inc. stock logo
SYBX
Synlogic
-$57.28M-$2.51N/AN/AN/AN/A-207.84%-114.81%5/13/2025 (Estimated)

Latest AQST, SYBX, LFVN, and SNSE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Synlogic, Inc. stock logo
SYBX
Synlogic
-$0.15N/AN/AN/AN/AN/A
5/12/2025Q1 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
5/6/2025Q1 2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$0.21-$0.27-$0.06-$0.27N/AN/A
3/28/2025Q4 2024
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$0.27-$0.27N/A-$0.31N/AN/A
3/6/2025Q4 2024
Synlogic, Inc. stock logo
SYBX
Synlogic
-$0.10-$0.06+$0.04-$0.06N/AN/A
3/5/2025Q4 2024
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.14-$0.19-$0.05-$0.19$13.11 million$11.87 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.52%N/A26.09%2 Years
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A

Latest AQST, SYBX, LFVN, and SNSE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
6.37
5.91
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/A
8.84
8.84
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
2.71
2.71

Institutional Ownership

CompanyInstitutional Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
10.50%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%

Insider Ownership

CompanyInsider Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
8.35%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
23.20%
Synlogic, Inc. stock logo
SYBX
Synlogic
3.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
16099.32 million84.02 millionOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
4025.21 million19.62 millionNot Optionable
Synlogic, Inc. stock logo
SYBX
Synlogic
8011.70 million11.34 millionOptionable

Recent News About These Companies

Synlogic (SYBX) Projected to Post Quarterly Earnings on Tuesday
Synlogic Reports Q3 2024 Financial Outcomes
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic, Inc. (0A8U.L)
MIN.SG,0P0001I7V6,0 (MIN.SG)
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
Synlogic Reports Second Quarter 2024 Financial Results
Synlogic Inc.
Synlogic Inc SYBX
Synlogic Flat on Q1 Numbers

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$2.85 +0.06 (+2.15%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$2.58 -0.27 (-9.47%)
As of 08:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$11.86 -0.41 (-3.34%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$12.53 +0.67 (+5.65%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Sensei Biotherapeutics stock logo

Sensei Biotherapeutics NASDAQ:SNSE

$0.36 +0.00 (+0.78%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$0.36 0.00 (-1.32%)
As of 08:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.13 +0.01 (+0.89%)
Closing price 05/12/2025 03:58 PM Eastern
Extended Trading
$1.10 -0.02 (-2.21%)
As of 05/12/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.